Collegium Pharmaceutical, Inc. (COLL) — Business segments and KPIs
Revenue by business segment and geography for Collegium Pharmaceutical, Inc., with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Belbuca | 221.65M | 35.9% |
| Xtampza ER | 199.31M | 32.3% |
| Nucynta IR | 115.31M | 18.7% |
| Nucynta ER | 80.99M | 13.1% |